TY - JOUR
T1 - Myeloablative conditioning for allo-HSCT in pediatric ALL
T2 - FTBI or chemotherapy?—A multicenter EBMT-PDWP study
AU - on behalf of the EBMT Paediatric Diseases Working Party
AU - Willasch, Andre Manfred
AU - Peters, Christina
AU - Sedláček, Petr
AU - Dalle, Jean Hugues
AU - Kitra-Roussou, Vassiliki
AU - Yesilipek, Akif
AU - Wachowiak, Jacek
AU - Lankester, Arjan
AU - Prete, Arcangelo
AU - Hamidieh, Amir Ali
AU - Ifversen, Marianne
AU - Buechner, Jochen
AU - Kriván, Gergely
AU - Hamladji, Rose Marie
AU - Diaz-de-Heredia, Cristina
AU - Skorobogatova, Elena
AU - Michel, Gérard
AU - Locatelli, Franco
AU - Bertaina, Alice
AU - Veys, Paul
AU - Dupont, Sophie
AU - Or, Reuven
AU - Güngör, Tayfun
AU - Aleinikova, Olga
AU - Sufliarska, Sabina
AU - Sundin, Mikael
AU - Rascon, Jelena
AU - Kaare, Ain
AU - Nemet, Damir
AU - Fagioli, Franca
AU - Klingebiel, Thomas Erich
AU - Styczynski, Jan
AU - Bierings, Marc
AU - Nagy, Kálmán
AU - Abecasis, Manuel
AU - Afanasyev, Boris
AU - Ansari, Marc
AU - Vettenranta, Kim
AU - Alseraihy, Amal
AU - Chybicka, Alicja
AU - Robinson, Stephen
AU - Bertrand, Yves
AU - Kupesiz, Alphan
AU - Ghavamzadeh, Ardeshir
AU - Campos, Antonio
AU - Pichler, Herbert
AU - Dalissier, Arnaud
AU - Labopin, Myriam
AU - Corbacioglu, Selim
AU - Balduzzi, Adriana
N1 - Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.
AB - Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.
UR - http://www.scopus.com/inward/record.url?scp=85082841595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082841595&partnerID=8YFLogxK
U2 - 10.1038/s41409-020-0854-0
DO - 10.1038/s41409-020-0854-0
M3 - Article
C2 - 32203263
AN - SCOPUS:85082841595
VL - 55
SP - 1540
EP - 1551
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 8
ER -